Comparative Pharmacology
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus REVEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUPRENORPHINE HYDROCHLORIDE NALOXONE HYDROCHLORIDE versus REVEX.
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE vs REVEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist (buprenorphine) and mu-opioid receptor antagonist (naloxone). Buprenorphine has high affinity but low intrinsic activity at mu receptors, producing ceiling effects on respiratory depression and euphoria. Naloxone antagonizes opioid effects and is poorly absorbed sublingually, added to discourage parenteral abuse.
Nalmefene is an opioid antagonist that competitively binds to mu, delta, and kappa opioid receptors, reversing or preventing opioid effects.
Sublingual: 2/0.5 mg to 4/1 mg once daily initially; titrate up to 8/2 mg, 12/3 mg, or 16/4 mg once daily; maximum 24/6 mg once daily. Buccal: 2.1/0.3 mg once daily initially; titrate up to 4.2/0.7 mg, 8.4/1.4 mg, or 12.6/2.1 mg once daily; maximum 12.6/2.1 mg once daily.
0.5 mg to 1 mg intravenous, intramuscular, or subcutaneous, repeated every 2 to 5 minutes as needed, up to a maximum of 2 mg total dose per episode.
None Documented
None Documented
Buprenorphine: terminal half-life 24-60 hours (mean ~37 h) due to slow dissociation from opioid receptors; clinically relevant for once-daily or alternate-day dosing. Naloxone: terminal half-life 1-2 hours; rapid elimination limits oral systemic availability.
Terminal elimination half-life: 2.4-4.2 hours in adults; prolonged in renal impairment (up to 50 hours).
Buprenorphine: primarily fecal (69-70%) via biliary excretion; renal (10-30%) as unchanged drug and metabolites. Naloxone: extensively metabolized in liver, primarily conjugated; renal excretion of metabolites (70%), minimal unchanged (<1%).
Renal: 60% as unchanged drug and metabolites; fecal: 40% via biliary elimination.
Category A/B
Category C
Opioid Antagonist
Opioid Antagonist